The AstraZeneca human monoclonal antibody binds to PD-L1 and blocks the interaction of PD-L1 with PD-1 and CD80, countering a tumour's immune-evading tactics.Original Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.